Molecular drug susceptibility testing in the Netherlands: performance of the MTBDRplus and MTBDRsl assays.
Int J Tuberc Lung Dis
; 19(7): 828-33, 2015 Jul.
Article
em En
| MEDLINE
| ID: mdl-26056110
ABSTRACT
BACKGROUND:
The performance of molecular drug susceptibility testing in countries with a low prevalence of drug resistance, such as the Netherlands, has not been adequately studied.OBJECTIVE:
To evaluate the diagnostic accuracy of the GenoType(®) MTBDRplus and MTBDRsl assays to detect resistance to first- and second-line anti-tuberculosis drugs in the context of a nationwide screening programme in the Netherlands.RESULTS:
The MTBDRplus assay had a sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of 100%, 99%, 80% and 100% for detecting rifampicin resistance. The sensitivity, specificity, PPV and NPV of either a katG or inhA mutation for detecting isoniazid resistance were 88%, 100%, 100% and 99%. The MTBDRsl assay had a sensitivity, specificity, PPV and NPV of 100%, 99%, 83%, and 100% for detecting moxifloxacin resistance; 62%, 71%, 58% and 74%, respectively, for detecting ethambutol resistance; 86%, 99%, 86% and 99% for detecting amikacin resistance; and 50%, 96%, 71% and 91% for detecting capreomycin resistance.CONCLUSION:
The MTBDRplus and MTBDRsl assays may aid in decision making in tuberculosis treatment in low-level drug resistance settings and should preferably be used to exclude resistance.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Farmacorresistência Bacteriana Múltipla
/
Tuberculose Extensivamente Resistente a Medicamentos
/
Mycobacterium tuberculosis
/
Antituberculosos
Tipo de estudo:
Diagnostic_studies
/
Evaluation_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
Europa
Idioma:
En
Revista:
Int J Tuberc Lung Dis
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Holanda